-
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)
Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Pamrevlumab: Unveiling the Potential of Anti-Fibrotic Therapy in Clinical Trials and Research(Post)Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver of
CTLA-4 in Breast Cancer: Insights for Immunotherapy(Post)The Role of CTLA-4 in Breast Cancer: Implications for ImmunotherapyBreast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, with significant morbidity and mortality
Liquid Biopsy and ctDNA: The New Frontier in Cancer Detection(Post)Imagine a future where a simple blood test could detect cancer in its earliest stages, long before symptoms appear. This isn't science fiction; it's the rapidly advancing reality of liquid biopsy, a r
Ruplizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What
Lusvertikimab: Unveiling the Potential in Immuno-Oncology(Post)What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,
Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r
Uliledlimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe
Biosimilar Antibodies(Page) 4-1BB: Energizing Immune Cells to Overcome Tumor Resistance(Post)Immunotherapy has become a central pillar in the fight against cancer, with a focus on enhancing the body’s natural defenses. Among the molecules at the forefront of immunotherapeutic res
Innate Immune System Explained: Step-by-Step Process & Key Concepts(Post)Immunology · Cell BiologyCells of the Innate Immune System: Types, Functions and MarkersThe innate immune system responds within minutes, without prior exposure, using cells that recognise conserved m
کیت سنجش فعالیت آنزیم تبدیل آنژیوتانسین II (ACE2)(Post)کیت سنجش فعالیت آنزیم تبدیل آنژیوتانسین II (ACE2) (فلورومتریک) آنزیم مبدل آنژیوتانسین II ، (ACE2, EC 3.4.17.23) یک متالوپروتاز
Immunopeptidomics: Mapping the Hidden Landscape of the Cancer Immunome(Post)Imagine a high-stakes game of hide-and-seek where the seeker is your immune system and the hider is a master of disguise: cancer. For decades, we believed the 'wanted' posters for tumor cells were li
ELISA High Background Troubleshooting: FBS Matrix Interference(Post)Quick answer A researcher running a Rat Eotaxin/CCL11 (Eotaxin) sandwich ELISA saw sample readings sit above the top standard and wells turn colour the instant TMB was added — even aft
The Next Leap in Cancer Treatment: CAR-T Cell Therapy's Journey to Mainstream Medicine(Post)For decades, the fight against cancer has been a grueling battle of attrition, with treatments often as harsh as the disease itself. But a revolutionary approach, chimeric antigen receptor (CAR)-T cel
Unlocking the Fortress: CAR-T Cell Therapy's Next Frontier in Solid Tumors(Post)For years, the success of CAR-T cell therapy has been a beacon of hope in the fight against blood cancers, offering remarkable remissions where other treatments have failed. Yet, solid tumors—the form
The Rise of Cancer Neuroscience: How Neural Circuits Drive Tumor Progression(Post)For decades, we viewed cancer as a rogue army of cells, a biological glitch driven solely by genetic mutations and metabolic greed. We imagined tumors as isolated fortresses, growing in a vacuum of t
Turning Tumors Against Themselves: In Vivo Reprogramming of Cancer Cells into Dendritic Sentinels(Post)Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaki